Each of thirteen drugs stays or goes in NU584's Unit 8 review mainly by one test: whether its benefit can arrive within a frail man's likely remaining years. Searches like "nu 584 unit 8 assignment example", "nu584 unit 8 sample" and "nu584 unit 8 example" land here.
Weeks, Months or Years: A Medication Burden Review That Sorts Thirteen Medicines by How Soon Each Pays Back
[Student Name]
Purdue University Global
NU584: AGNP II - Primary Care of the Frail Elderly
Unit 8 Medication Burden Review
[Instructor Name]
[Date]
The patient is a composite; doses, estimates and dates are bracketed, and each action is a proposal for the prescriber.
The Patient and His Priority
Mr. [P.], 85, worked as a pipefitter for forty years. Clinical Frailty Scale [6]: moderately frail, needing help with bathing and outdoor activities. His estimated prognosis, from a published index for community-dwelling older adults, is [two to four] years, with the uncertainty stated plainly: indices estimate groups, not individuals. His priority, in his words: "Stay out of the hospital and keep my mind clear."
A drug whose benefit takes longer to arrive than a person's likely remaining time offers him mostly its risks. That comparison, time to benefit set against time remaining, is the frame proposed for medication decisions late in life (Holmes et al., 2006).
Band 1: Weeks
Benefits he feels now.
1. [Acetaminophen] 650 mg three times daily for knee osteoarthritis. Beers flag: none. Action: keep; confirm the total stays under 3 g a day.
2. [Tamsulosin] 0.4 mg at bedtime for urinary symptoms. Beers flag: caution for orthostatic hypotension. Action: keep; check standing blood pressure.
3. [Furosemide] 20 mg daily for ankle edema. Action: keep at the lowest dose that controls edema.
4. [Tramadol] 50 mg twice daily for back pain. Beers flag: use with caution; risk of low sodium and seizures. Action: keep for now, with sodium checked; see the START omission below.
START omission: no laxative prescribed beside regular tramadol. STOPP/START version 3 lists a laxative for patients on regular opioids as an omission to correct (O'Mahony et al., 2023). Action: add [senna] at bedtime.
Band 2: Months
1. [Apixaban] 2.5 mg twice daily for atrial fibrillation, dose adjusted for age and weight. Action: keep. Stroke prevention accrues within months, and fall risk alone rarely outweighs the benefit of anticoagulation in atrial fibrillation.
2. [Alendronate] 70 mg weekly for osteoporosis, after a wrist fracture two years ago. Action: keep, since fracture reduction begins within about a year; confirm he can sit upright for thirty minutes after each dose.
Band 3: Years
Most of the pills and the least of the value.
1. [Aspirin] 81 mg daily, started years ago for primary prevention. STOPP flags an antiplatelet with an anticoagulant without a clear indication. Action: stop.
2. [Glipizide] 5 mg daily, pursuing an A1C near 7 percent. Action: withdraw, tapering over [two] weeks, with a looser target below 8.0 percent; hypoglycemia is an immediate risk, and the microvascular benefit of tight control takes many years.
3. [Chlorthalidone] 12.5 mg daily, the third antihypertensive added to reach a target of 130/80. Action: taper and stop, with standing blood pressure checked; a less stringent target is appropriate at his frailty level, and his orthostatic symptoms argue against the tight one.
4. [Atorvastatin] 40 mg daily for primary prevention. Action: discuss with him. A pooled analysis of primary prevention trials in adults 50 to 75 estimated about 2.5 years before statins prevent one major cardiovascular event for every hundred people treated (Yourman et al., 2021); few trial participants were his age, and he has two to four years. Continuing is reasonable if he values it; stopping is reasonable if pill burden or muscle aches bother him.
5. [Lisinopril] 20 mg and [amlodipine] 5 mg. Action: keep, pending the chlorthalidone taper, then reassess.
6. [Omeprazole] 20 mg daily, no documented indication. Beers flag: long-term use without a documented reason is on the list to avoid (American Geriatrics Society Beers Criteria Update Expert Panel, 2023). Action: taper and stop.
What the Prognostic Estimate Can and Cannot Do
The estimate of two to four years is a population figure. Among a hundred men with his age, conditions and function, many will live longer and some shorter, and the index cannot say which he will be. The review uses it to set the time frame for comparing benefits, not to predict his death, and it was shared with him in those terms. What matters is less the precise number than the direction it points: a drug whose benefit takes ten years to arrive is unlikely to help a man with this profile, while one whose benefit arrives in weeks almost certainly will. Where a drug sits near the boundary, as the statin does, the decision goes to his preference rather than the estimate.
How the Conversation Went
Mr. [P.] listened to the three bands and said, "So the ones for later, I can let go of." He asked to stop the aspirin and the extra blood pressure pill that makes him dizzy, and he was glad to lose the glipizide once he heard it could cause confusion, which he fears. He hesitated on the statin: his brother had a heart attack at 70. After hearing the time-to-benefit estimate and that stopping would not cause harm quickly, he chose to keep it for now and revisit at the next visit. The decision is his, and the review records it as his.
Sequencing Across Visits
Visit 1: stop aspirin; start the glipizide taper; add senna. Visit 2, in [four] weeks: begin the chlorthalidone taper; review glucose and standing pressure. Visit 3, in [eight] weeks: omeprazole taper; statin conversation. Only one or two changes at a time, so any new symptom can be traced.
Why This Frame Fits His Priority
His priority, staying out of the hospital and keeping his mind clear, is served by removing the drugs most likely to put him there: a sulfonylurea that causes hypoglycemia and confusion, an extra blood pressure pill that makes him lightheaded, and an antiplatelet that adds bleeding risk to his anticoagulant. The drugs kept are the ones whose benefit arrives in time for him to have it.
Monitoring After the Changes
Stopping medicines carries its own risks, and each change has a check. After the glipizide taper, his glucose log is reviewed at two weeks for readings above [250] mg/dL, which would prompt a different, low-risk agent rather than a return to the sulfonylurea. After the chlorthalidone taper, his seated and standing blood pressure are rechecked at four weeks; a seated reading above [160] would prompt reconsideration. After the omeprazole taper, rebound heartburn is expected for a week or two and does not mean the drug was needed. If any change causes a problem, it is reversed, and the review is updated so the next clinician sees what was tried.
References
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372
Holmes, H. M., Hayley, D. C., Alexander, G. C., & Sachs, G. A. (2006). Reconsidering medication appropriateness for patients late in life. Archives of Internal Medicine, 166(6), 605-609. https://doi.org/10.1001/archinte.166.6.605
O'Mahony, D., Cherubini, A., Guiteras, A. R., Denkinger, M., Beuscart, J.-B., Onder, G., Gudmundsson, A., Cruz-Jentoft, A. J., Knol, W., Bahat, G., van der Velde, N., Petrovic, M., & Curtin, D. (2023). STOPP/START criteria for potentially inappropriate prescribing in older people: Version 3. European Geriatric Medicine, 14(4), 625-632. https://doi.org/10.1007/s41999-023-00777-y
Yourman, L. C., Cenzer, I. S., Boscardin, W. J., Nguyen, B. T., Smith, A. K., Schonberg, M. A., Schoenborn, N. L., Widera, E. W., Orkaby, A., Rodriguez, A., & Lee, S. J. (2021). Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: A meta-analysis. JAMA Internal Medicine, 181(2), 179-185. https://doi.org/10.1001/jamainternmed.2020.6084
How this NU584 Unit 8 example is structured
Horizon organizes the review because horizon is what frailty changes. The introduction sets the comparison explicitly: a drug whose benefit takes longer to arrive than his likely remaining time offers mostly risk, and the paper names the prognostic tool and admits its imprecision. Within each band, rows are ordered by harm. The weeks band is mostly kept, with dosing checked. The months band keeps apixaban, reasoning that stroke prevention accrues quickly and that fall risk alone rarely outweighs it, and questions alendronate only on adherence. The years band carries the proposals: aspirin stopped, since STOPP flags an antiplatelet beside an anticoagulant without a clear indication; glipizide withdrawn in favor of a looser target; the third antihypertensive tapered; atorvastatin discussed with him, citing statin time-to-benefit data (Yourman and colleagues, 2021) and how few trial participants were his age. Changes are sequenced across visits.
Get an NU584 Unit 8 example written to your instructions
Paste every medication in your Unit 8 scenario, with the frailty details and any goals the scenario records, plus the rubric. We place every drug in a benefit-horizon band of weeks, months or years, screen against Beers 2023 and STOPP/START, and write the proposals for the prescriber in a sequence. Free on first request, back in 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU584 Unit 8 questions, answered
What is STOPP/START?
A pair of explicit criteria sets from Europe: STOPP lists potentially inappropriate prescriptions in older adults, and START lists potentially beneficial drugs that are missing. Version 3, published in 2023, is current. It complements the Beers Criteria, and START in particular catches omissions that Beers does not address. Cite the version number in the paper.
Where do time-to-benefit estimates come from?
From analyses of trial data that ask how long it takes for treated patients to show a measurable advantage over controls, such as preventing one event per hundred people treated. Estimates exist for statins, blood pressure control, glucose control and bisphosphonates. Cite the source for each, and note when the trials enrolled few people as old as the patient.
Should a frail patient's anticoagulant be stopped because of falls?
Not on that ground alone, in most analyses. Stroke prevention in atrial fibrillation begins early, and falls rarely shift the balance enough by themselves. The decision depends on bleeding history, kidney function and goals of care, and it belongs to the prescriber with the patient. A paper should show that reasoning instead of assuming falls end the discussion.